Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1954 1
1957 1
1958 1
1962 3
1964 1
1966 2
1968 2
1969 2
1970 2
1971 2
1972 1
1973 1
1974 2
1975 3
1977 3
1979 1
1980 3
1981 2
1982 2
1983 2
1984 1
1986 2
1987 1
1989 3
1990 1
1992 1
1994 1
1995 1
1996 2
1997 1
1998 1
1999 2
2000 1
2001 3
2002 5
2003 2
2004 5
2005 9
2006 9
2007 13
2008 19
2009 15
2010 20
2011 43
2012 53
2013 68
2014 67
2015 86
2016 61
2017 61
2018 63
2019 76
2020 79
2021 78
2022 70
2023 74
2024 64

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

975 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease.
Park S, Park CW, Eom JH, Jo MY, Hur HJ, Choi SK, Lee JS, Nam ST, Jo KS, Oh YW, Lee J, Kim S, Kim DH, Park CY, Kim SJ, Lee HY, Cho MS, Kim DS, Kim DW. Park S, et al. Among authors: jo ks. Cell Stem Cell. 2024 Jan 4;31(1):25-38.e8. doi: 10.1016/j.stem.2023.11.009. Epub 2023 Dec 11. Cell Stem Cell. 2024. PMID: 38086390 Free article.
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Among authors: jo kw. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
Beyond the survey, to the ideal therapy for Asian.
Jo KJ, Im JP. Jo KJ, et al. Intest Res. 2023 Jul;21(3):280-282. doi: 10.5217/ir.2023.00075. Epub 2023 Jul 27. Intest Res. 2023. PMID: 37533263 Free PMC article. No abstract available.
USP37 Deubiquitinates CDC73 in HPT-JT Syndrome.
Kim SY, Lee JY, Cho YJ, Jo KH, Kim ES, Han JH, Baek KH, Moon SD. Kim SY, et al. Among authors: jo kh. Int J Mol Sci. 2022 Jun 7;23(12):6364. doi: 10.3390/ijms23126364. Int J Mol Sci. 2022. PMID: 35742816 Free PMC article.
Current status of platelet manufacturing in 3D or bioreactors.
Kweon S, Kim S, Choi HS, Jo K, Park JM, Baek EJ. Kweon S, et al. Among authors: jo k. Biotechnol Prog. 2023 Sep-Oct;39(5):e3364. doi: 10.1002/btpr.3364. Epub 2023 Jun 9. Biotechnol Prog. 2023. PMID: 37294031 Review.
975 results